Metformin Aurobindo (Metformin Hydrochloride)

Metformin Aurobindo belongs to the biguanide class and is used to improve glycaemic control in disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes.
• Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

• Metformin Hydrochloride reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). These actions collectively lower circulating glucose without stimulating insulin secretion, helping to maintain stable blood‑sugar levels in patients with insulin resistance.

Metformin Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite.
• Diarrhea: frequent loose stools, especially during treatment initiation.
• Metallic taste: transient alteration in taste perception.
• Flatulence: increased intestinal gas.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatotoxicity: abnormal liver enzymes indicating liver injury.
• Vitamin B12 deficiency: may develop with long‑term therapy.
• Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents.

Before initiating Metformin Aurobindo, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

• Renal function: assess creatinine clearance and avoid use in severe renal impairment.
• Hepatic function: check liver enzymes; avoid in active liver disease.
• Risk of lactic acidosis: consider comorbidities such as heart failure, hypoxia, or sepsis.
• Elderly patients: start at lower doses and monitor tolerance closely.
• Vitamin B12 status: periodic testing is advisable during prolonged therapy.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Aurobindo can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Alcohol (excessive): enhances risk of lactic acidosis.
• Diuretics (e.g., thiazides): may impair renal clearance of metformin.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: monitor renal function when combined.
• Other antidiabetic agents (e.g., sulfonylureas): increase risk of hypoglycaemia.
• CYP450 inhibitors (e.g., trimethoprim): may affect renal handling of metformin.